Kuehn Law, PLLC is investigating whether certain officers and directors of Corcept Therapeutics Incorporated breached their fiduciary duties to shareholders regarding the disclosure of risks associated with relacorilant. The investigation follows a federal securities lawsuit alleging the company failed to disclose adverse facts concerning the potential FDA approval of the drug, a treatment for hypercortisolism, or Cushing's syndrome. The lawsuit claims that while Corcept touted the expected success of FDA approval, it did not reveal that the FDA had expressed concerns about the adequacy of its clinical development program and that the New Drug Application faced a material risk of rejection.

The firm is encouraging shareholders who purchased Corcept stock prior to October 31, 2024, to contact Justin Kuehn, Esq. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders are advised to contact the firm immediately due to potential time limits to enforce rights.

Corcept Therapeutics Incorporated recently resubmitted its New Drug Application (NDA) for relacorilant to the U.S. Food and Drug Administration (FDA). The resubmission includes additional analyses of data from the original submission, as requested by the FDA, and is expected to receive a six-month review. The application is supported by data from the pivotal GRACE trial, the Phase III GRADIENT trial, and a long-term extension study.

Relacorilant is an oral therapy and selective glucocorticoid receptor antagonist. It has been designated an orphan drug by the FDA and the European Commission for the treatment of hypercortisolism. Under the brand name Lifyorli, relacorilant was approved in combination with nab-paclitaxel for adults with platinum-resistant ovarian cancer by the FDA in 2026.

Hypercortisolism is caused by excessive cortisol activity and can lead to hypertension, central obesity, and type 2 diabetes. If untreated, the condition can be fatal, with cardiovascular events being the most common cause of death.